Which has the lower trailing P/E, ANIP or OMCL?

ANIP has the lower trailing P/E: ANIP trades at 15.45 and OMCL at 41.97. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ANIP or OMCL?

Over the past five years, ANIP grew revenue faster — ANIP at a 35.61% CAGR versus OMCL at 4.77%.

Is ANIP or OMCL more profitable?

ANIP runs the higher net margin — ANIP at 10.82% versus OMCL at 3.13%.

How have ANIP and OMCL total returns compared?

Over the past 10 years, ANIP delivered 0.51% and OMCL delivered -0.80% annualized total return. Past performance doesn't predict future results.

ANI Pharmaceuticals, Inc. (ANIP) vs Omnicell, Inc. (OMCL)

A side-by-side comparison of ANI Pharmaceuticals, Inc. and Omnicell, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ANIP

ANI Pharmaceuticals, Inc.

$1.63B

$71.52HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

OMCL

Omnicell, Inc.

$1.61B

$35.46HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — ANIP vs OMCL

growth of $100 · dividends reinvested · last 10y

ANIP +5.2% (+0.5%/yr)OMCL -7.5% (-0.8%/yr)ANIP compounded faster over this window

ANIP OMCL

ANIP vs OMCL: by the numbers

•ANIP is the larger company ($1.63B vs $1.61B market cap).
•ANIP trades at the lower trailing earnings multiple (15.45 vs 41.97 P/E), one valuation lens rather than an overall verdict.
•ANIP converts more revenue to profit (10.82% vs 3.13% net margin).
•ANIP grew revenue faster over the past five years (35.61% vs 4.77% CAGR).

Metrics side by side

Valuation

Metric	ANIP	OMCL
P/E ratio	15.45	41.97
Forward P/E	7.71	15.63
P/S ratio	1.66	1.29
P/B ratio	2.72	1.25
EV / EBITDA	6.76	10.75
FCF yield	N/A	8.77%

Profitability

Metric	ANIP	OMCL
Gross margin	51.01%	44.77%
Operating margin	15.35%	4.73%
Net margin	10.82%	3.13%
ROE	17.72%	3.03%
ROIC	9.26%	2.43%

Growth (annualized)

Metric	ANIP	OMCL
Revenue CAGR (5Y)	35.61%	4.77%
EPS CAGR (5Y)	N/A	-43.29%
FCF CAGR (5Y)	N/A	-8.10%
Total return CAGR (5Y)	16.86%	-26.44%

Frequently asked

Which has the lower trailing P/E, ANIP or OMCL?: ANIP has the lower trailing P/E: ANIP trades at 15.45 and OMCL at 41.97. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ANIP or OMCL?: Over the past five years, ANIP grew revenue faster — ANIP at a 35.61% CAGR versus OMCL at 4.77%.
Is ANIP or OMCL more profitable?: ANIP runs the higher net margin — ANIP at 10.82% versus OMCL at 3.13%.
How have ANIP and OMCL total returns compared?: Over the past 10 years, ANIP delivered 0.51% and OMCL delivered -0.80% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ANIP analysis Full OMCL analysis Interactive comparison tool

Dig into the metrics

ANI Pharmaceuticals P/E ratio Omnicell P/E ratio ANI Pharmaceuticals ROE Omnicell ROE ANI Pharmaceuticals operating margin Omnicell operating margin ANI Pharmaceuticals revenue growth Omnicell revenue growth ANI Pharmaceuticals free cash flow Omnicell free cash flow

ANI Pharmaceuticals & Omnicell appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.